Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow CMND by emailGet an email when CMND pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about CMND, unsubscribe in one click. Privacy
📣 What CMND Says Is Next
by 2032 · “According to Data Bridge Market Research, the global alcohol-dependency treatment market was valued at approximately $13.2 billion in 2024 and is projected to reach about $20 billion by 2032, illustrating the substantial unmet need and commercial opportunity for new therapeutic approaches.”
Company press release, Oct 30, 2025 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full CMND picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CMND and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.